Pfizer Lyrica Review Notable For Complexity: Four NDAs, Three FDA Divisions
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Pfizer’s Lyrica (pregabalin) application may be one of the most exhaustively reviewed NDAs of the user fee era, Lyrica’s complex regulatory history suggests.